Usefulness of Whole-Body Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Patients with Neurofibromatosis Type 1: A Systematic Review

Table 1

Characteristics of the included articles and patients.

Authors	Journal	Year	Country	PET device	Number of patients with neurogenic tumors who performed PET (in brackets patients with NF1)	Sex; (% male)	Mean age (years)	Number of neurogenic tumor lesions evaluated
Ferner et al. [9]	J Neurol Neurosurg Psychiatry	2000	UK	PET	18 (18)	44%	28	23
Cardona et al. [10]	Eur J Surg Oncol	2003	Germany	PET	13 (5)	38%	46	25
Wegner et al. [11]	Eur J Nucl Med Mol Imaging	2005	UK	PET	13 (n.a.)	46%	15	n.a.
Brenner et al. [12]	Eur J Nucl Med Mol Imaging	2006	Germany	PET	16 (16)	44%	32	16
Bensaid et al. [13]	Ann Dermatol Venereol	2007	France	PET	38 (38)	n.a.	n.a.	49
Bredella et al. [14]	AJR Am J Roentgenol	2007	USA	PET and PET/CT	45 (45)	49%	37	50
Ferner et al. [15]	Ann Oncol	2008	UK	PET and PET/CT	105 (105)	48%	31	114
Fisher et al. [16]	J Neurooncol	2008	USA	PET	18 (18)	50%	14	19
Karabatsou et al. [17]	Neurosurgery	2009	Canada	PET/CT	9 (9)	55%	38	9
Warbey et al. [18]	Eur J Nucl Med Mol Imaging	2009	UK	PET/CT	62 (62)	50%	31	85
Benz et al. [19]	Cancer	2010	Germany/USA	PET/CT	34 (5)	59%	46	40
Moharir et al. [20]	Eur J Nucl Med Mol Imaging	2010	Canada/Australia	PET/CT	18 (18)	44%	8	35

n.a.: not applicable.